Milan, Italy – Veritas, The Genome Company, solidified its position at the forefront of genetic innovation through a significant and impactful presence at the European Human Genetics Conference (ESHG) 2025, held from May 24 to 27 in Milan, Italy. As the leading scientific and professional event in human genetics, ESHG 2025 convened thousands of top experts, researchers, and clinicians from across Europe and the globe, offering an unparalleled platform for sharing advancements and fostering collaboration.

At ESHG 2025, Veritas actively engaged with attendees, showcasing our comprehensive and broad portfolio of genomic services, which underscores the company’s unwavering commitment to advancing precision health across diverse applications, including Whole Genome and Exome Sequencing for comprehensive genomic data, pharmacogenomics for optimizing drug therapy, prenatal medicine for advanced reproductive health insights, Polygenic Risk Scores (PRS) for proactive disease prevention and genetic diagnosis for rare and inherited conditions.

A highlight of our participation was the presentation of groundbreaking research from its dedicated scientific team, demonstrated through two compelling posters. This pioneering work focused on the critical impact of global genetic sequencing in the early diagnosis of primary immunodeficiencies, a field where timely and accurate identification can significantly alter patient outcomes.

• “Early diagnosis of ELANE-related neutropenia” presented by Dr. Irene Parea. This study provided crucial insights into the advantages of early genetic identification for ELANE-related neutropenia, emphasizing how precise diagnosis can lead to more effective and individualized clinical management from an early stage.
• “X-linked primary immunodeficiencies: novel BTK and WAS variants” presented by Dr. Enrique Fernández. Dr. Fernández’s research unveiled novel genetic variants associated with X-linked primary immunodeficiencies (X-linked agammaglobulinemia related to BTK gene and Wiskott-Aldrich syndrome related to WAS gene), deepening the understanding of these complex conditions and paving the way for improved diagnostic tools and therapeutic approaches.

The company’s contributions at ESHG 2025 exemplify its mission to translate complex genomic discoveries into actionable clinical insights, ultimately improving patient care and advancing global health initiatives.